肌萎缩侧索硬化
神经科学
神经炎症
小胶质细胞
再生(生物学)
调节器
中枢神经系统
运动神经元
生物
转基因
效应器
神经肌肉接头
医学
转基因小鼠
突触
治疗方法
双重角色
瓦勒氏变性
神经退行性变
轴突
轴浆运输
遗传增强
神经系统
损失函数
神经可塑性
疾病
神经保护
多发性硬化
电动机系统
突触可塑性
功能(生物学)
退行性疾病
作者
Chen Liang,Tongtong Cui,Bingyu Cai,Yali Ding,Jinjie Chang,Wenhui Huang,Zongbao Lu,Jiabao Han,Qi Gu,Ying Zhang,Wei Li,Fei Teng
出处
期刊:Cell Reports
[Cell Press]
日期:2026-11-01
卷期号:45 (11): 118305-118305
标识
DOI:10.1016/j.celrep.2026.118305
摘要
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder primarily driven by TAR DNA-binding protein 43 (TDP-43) proteinopathy, which triggers early axonal disintegration and disrupts central nervous system homeostasis. Current therapeutic options remain limited. To address these core pathologies, we developed a dual-gene therapeutic strategy that simultaneously restores two pivotal factors: progranulin (GRN), a multifunctional effector critical for lysosomal function and neuroinflammation regulation, and stathmin-2 (STMN2), an essential regulator of axonal integrity and regeneration whose loss is directly linked to TDP-43 pathology. In TDP-43 A315T transgenic mice, this combined therapy significantly extended survival, preserved motor performance, and maintained neuromuscular integrity. In human iPSC-derived motor neurons, the dual therapy promoted axonal regeneration following injury. Mechanistically, treatment coordinately restored axonal and synaptic gene programs in motor neurons while upregulating lysosomal pathways in microglia and neuronal support genes in astrocytes, collectively rebalancing neuronal and glial function. These findings establish that dual augmentation of GRN and STMN2 represents a potential therapeutic strategy for ALS.
科研通智能强力驱动
Strongly Powered by AbleSci AI